title: Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
abstract: This multicenter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C infection compared treatment with consensus interferon (CIFN), a non-natural recombinant type-1 interferon, with a standard regimen of recombinant interferon alfa-2b (IFN-alpha2b). Patients were randomized to receive CIFN at doses of 3 microg or 9 microg, or 15 microg IFN-alpha2b (3 million units), subcutaneously three times weekly for 24 weeks, followed by 24 weeks of observation. Efficacy was assessed by normalization of serum alanine transaminase (ALT) concentration and decrease in serum hepatitis C virus (HCV) RNA concentration below the limit of detection by reverse-transcription polymerase chain reaction (RT-PCR) (100 copies/mL). The beneficial effect of CIFN was greater with the 9-microg dose than the 3-microg dose. The sustained ALT and HCV RNA response rates were 20.3% and 12.1%, respectively, in the 9-microg CIFN cohort and 19.6% and 11.3%, respectively, in the 15-microg IFN-alpha2b cohort. However, patients receiving 9 microg of CIFN had a greater reduction in serum HCV RNA concentrations compared with patients receiving 15 microg IFN-alpha2b over the course of treatment (P < .01). Similarly, analysis of patients infected with HCV genotype 1 showed a greater reduction in serum HCV RNA concentration over the course of treatment for the 9-microg CIFN group when compared with the 15-microg IFN-alpha2b group (P < .01). In addition, a greater percentage of patients infected with HCV genotype 1 treated with 9 microg CIFN had undetectable HCV RNA concentrations when compared with patients in the 15-microg IFN-alpha2b cohort at the end of treatment (24% vs. 15%; P = .04). Improvements in liver histology were noted in all three treatment groups; 52% to 55% of the patients in the three cohorts had at least a 2-unit improvement in the Knodell score at the end of the posttreatment period. The adverse-events profiles were characteristic of treatment with type-1 interferon, and the incidences of anti-interferon antibody formation did not significantly differ among the three treatment groups. These results show that administration of 9 microg CIFN three times weekly for 6 months is safe and is effective in reducing serum HCV RNA concentration.
authors.affiliation: Huntington Memorial Hospital, Pasadena, CA 91105, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Tong
authors.forename: K R
authors.initials: KR
authors.lastname: Reddy
authors.forename: W M
authors.initials: WM
authors.lastname: Lee
authors.forename: P J
authors.initials: PJ
authors.lastname: Pockros
authors.forename: J C
authors.initials: JC
authors.lastname: Hoefs
authors.forename: E B
authors.initials: EB
authors.lastname: Keeffe
authors.forename: F B
authors.initials: FB
authors.lastname: Hollinger
authors.forename: E J
authors.initials: EJ
authors.lastname: Hathcote
authors.forename: H
authors.initials: H
authors.lastname: White
authors.forename: R T
authors.initials: RT
authors.lastname: Foust
authors.forename: D M
authors.initials: DM
authors.lastname: Jensen
authors.forename: E L
authors.initials: EL
authors.lastname: Krawitt
authors.forename: H
authors.initials: H
authors.lastname: Fromm
authors.forename: M
authors.initials: M
authors.lastname: Black
authors.forename: L M
authors.initials: LM
authors.lastname: Blatt
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: J
authors.initials: J
authors.lastname: Lubina
mesh_terms: D000328:Adult; D000917:Antibody Formation; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D012367:RNA, Viral / Q000235:genetics; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; C050739:interferon alfacon-1